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Introduction
According to the World Health Organization (WHO), depression is 
one of the most prevalent disorders, affecting an estimated 4.4% 
of the global population, and is the single largest contributor to 
disability worldwide (contributing 7.5% of all years lived with 
disability in 2015).1,2 More than 80% of this disease burden is 
carried by low- and middle- income countries (LMICs) with 16% 
of all cases of depressive disorders residing in Africa.3,4 In South 
Africa, the lifetime and 12-month prevalence rates for major 
depressive disorder are 9.7% and 4.9%, respectively, with less 
than a quarter of South Africans with major depressive disorder 
able to access services and receive treatment.4 Depressive 
disorders are also a major contributor to death by suicide. In 
adults, depressive disorders increase in prevalence in the 20- to 
30-year age group and continue to increase in middle age. These 
disorders are more common in individuals who are unmarried, 
divorced or widowed (compared to individuals who are married); 
in those who have suffered traumatic life events; and those who 
have a family history of depression. Women have a twofold 
greater risk of developing depression than men, with this gender 
differential manifesting at puberty. The course of depression 
is variable, both in terms of chronicity and remission. The 
probability of recurrence is also very high with approximately 
80% of patients who achieve remission experiencing at least one 
recurrence in their lifetime. Psychiatric comorbidity (e.g. anxiety 
disorders, alcohol and drug-use disorders), history of childhood 
trauma, and greater severity of a depressive episode all predict a 
less favourable course.5
Reducing the incidence and prevalence of depression is a major 
public health priority. Similar to other LMICs, South Africa suffers 
from an absence of qualified mental health care workers. Only 
0.9% of all registered psychiatrists in SA practise in primary 
health care settings.6 From this perspective, there is a key 
need to integrate the management of depression into general 
medical care, consistent with evidence from around the world 
highlighting the value of collaborative care.7 In view of the high 
prevalence of depression, escalating healthcare costs, shortage 
of mental health professionals, and high rates of medical 
comorbidity associated with depression (e.g. cardiovascular 
disease), uncomplicated depression should ideally be recognised 
and managed at primary care level. Family physicians and 
general practitioners therefore need to be well equipped to 
diagnose and treat depressive disorders.
The Diagnostic and Statistical Manual of Mental Disorders, 5th 
Edition (DSM-5) introduced several updates and changes to the 
chapter on depressive disorders.8 Changes to the DSM were 
largely informed by advances in neuroscience, clinical and public 
health needs and difficulties identified with the previous DSM-IV 
classification system and criteria. Much of the decision-making 
that informed the DSM-5 was also to ensure better alignment 
with the International Classification of Diseases and its upcoming 
11th edition (ICD-11).9
This review outlines some of the major changes including 
the introduction of two new disorders: disruptive mood 
dysregulation disorder (DMDD) and premenstrual dysphoric 
disorder (PMDD). We discuss a diagnostic approach, appropriate 
use of subtyping and specifiers, and lastly a comprehensive 
management plan that addresses these changes. 
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Abstract
Depressive disorders comprise a range of conditions that can be viewed along many dimensions. The Diagnostic and Statistical 
Manual of Mental Disorders, 5th Edition (DSM-5) introduced several changes to the chapter on depressive disorders largely 
informed by advances in neuroscience, clinical and public health needs and difficulties identified with the previous DSM-IV 
classification system and criteria. Clinical characteristics vary across depressive disorders, as do the corresponding treatments. 
Pharmacotherapy and psychotherapy should be tailored to the individual patient. 
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Diagnosis and identification
Depression carries a wide differential diagnosis. If a depressive 
episode is diagnosed it is important to ascertain whether the 
depressive episode is part of a depressive disorder or another 
psychiatric or medical illness. MDD also needs to be differentiated 
from normal sadness or bereavement although in patients who 
are grieving, if depressive symptoms are severe and persistent, 
a diagnosis of MDD can be made. An accurate diagnosis can be 
determined through detailed history taking, mental status and 
physical examination, and supplementary laboratory tests as 
indicated. 
DSM-5 Depressive Disorders
The DSM-5 depressive disorders include: disruptive mood 
dysregulation disorder, major depressive disorder (including 
major depressive episode), persistent depressive disorders 
(dysthymia), premenstrual dysphoric disorder, substance/
medication-induced depressive disorder, depressive disorder 
due to another medical condition, and other specified and 
unspecified depressive disorders.8
Disruptive Mood Dysregulation Disorder (DMDD)
This new disorder was included due to concerns that bipolar 
disorder was being overdiagnosed and treated in children. 
It refers to persistent irritability and frequent episodes of 
behavioural dyscontrol in children up to 12 years of age.10 
Community surveys have estimated a prevalence of DMDD of 
2 – 5% with a male preponderance.10
Major Depressive Disorder
As a syndrome, MDD is defined by a constellation of features that 
are related not only to mood but also to sleep, energy, cognition, 
motivation, and motor behavior persisting for ≥ 2 weeks. The 
DSM-5 criteria for a major depressive episode are as follows:
Five or more out of 9 symptoms (including either depressed 
mood, or loss of interest or pleasure) in the same 2-week period. 
Each of these symptoms represents a change from previous 
functioning, and needs to be present nearly every day:
1. Depressed mood (subjective or observed); can be an irritable 
mood in children and adolescents, most of the day;
2. Loss of interest or pleasure, most of the day;
3. Change in weight or appetite. Weight: 5% change over 
1 month;
4. Insomnia or hypersomnia;
5. Psychomotor retardation or agitation (observed);
6. Loss of energy, or fatigue;
7. Worthlessness or guilt;
8. Impaired concentration or indecisiveness; or
9. Recurrent thoughts of death or suicidal ideation or attempt.
In the DSM-5 bereavement, formerly an exclusion criterion, no 
longer precludes making a diagnosis of MDD when syndromal 
criteria are otherwise fulfilled.
Persistent Depressive Disorder (Dysthymia)
DSM-5 has subsumed chronic major depression and dysthymia 
under the unified heading of persistent depressive disorder. 
Persistent depressive disorder (PDD) is chronic (depressive 
symptoms persist for more than 2 years). In addition to a 
pervasive depressed mood, only 2 of 6 symptoms are required 
for the diagnosis (sleep disturbance, appetite disturbance, 
loss of energy, decreased self-esteem, hopelessness, or poor 
concentration). If a patient meets criteria for MDD, then both 
diagnoses can be made (i.e. MDD and PDD).
Premenstrual Dysphoric Disorder (PMDD)
PMDD is a new category in DSM-5 that describes a constellation 
of affective, behavioural, cognitive and physical symptoms. 
A distinguishing characteristic of PMDD is the timing of symptom 
onset. In women with PMDD, mood symptoms occur only during 
the luteal phase of the menstrual cycle (ovulation until onset 
of menses) and resolve after menstruation onset. Women with 
PMDD report normal mood and functioning during the follicular 
phase of the menstrual cycle (first day of the menstrual cycle until 
ovulation). As such, PMDD consists of intermittently occurring 
symptoms, but is also characterised by mental state changes 
and impairment of functionality. PMDD is frequently missed, 
particularly as the clinical evaluation may not coincide with 
symptom occurrence, or there may be clinician unawareness or 
failure of patients to recognise that intermittent symptoms are 
treatable. The diagnosis is made when a patient has at least 5 of 
11 specific symptoms (marked depressed mood, marked anxiety, 
marked affective lability [e.g. feeling suddenly sad or fearful, or 
heightened sensitivity to rejection], persistent or marked anger or 
irritability, sleep disturbances, appetite disturbances, decreased 
energy or lethargy, concentration problems, decreased interest, 
feeling overwhelmed or out of control, and other physical 
symptoms [e.g. breast tenderness, headache, bloating]) that 
occur during the week before menses onset, and improve within 
a few days after the onset of menses.The symptoms are severe 
enough to interfere significantly with social, occupational, 
scholastic or sexual functioning. A systematic approach to the 
diagnosis of PMDD is essential and should include ruling out a 
premenstrual exacerbation of another underlying or comorbid 
mood, anxiety or physical disorder.11,12.
Substance/Medication-induced Depressive Disorder
This diagnosis can be made when depressive symptoms appear 
during or within one  month after using a substance and there 
is confirmatory evidence from the patient’s history, physical 
examination, or laboratory findings of substance use, abuse, 
intoxication, or withdrawal prior to the start of the depressive 
symptoms.
Depressive Disorder due to another medical condition
To arrive at a primary psychiatric diagnosis, all potential 
secondary causes must be ruled out. This includes systematic 
screening for possible drug-induced psychopathology related 
not only to drugs of abuse, but also to prescription medications, 
some of which can have serious iatrogenic effects, including 
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depression. The other important cause to rule out is the 
possibility of a general medical condition triggering psychiatric 
symptoms, which requires targeted questioning about medical 
history, a review of organ systems, and ordering key laboratory 
tests. In the DSM-5, depressive episodes that arise secondary to 
a medical condition (e.g. hypothyroidism), substance abuse (e.g. 
alcohol), or iatrogenically from medications (e.g. corticosteroids, 
oral contraceptives) are viewed as distinct from MDD in regard to 
risk of recurrence, and neurobiological underpinnings.
Other Specified and Unspecified Depressive Disorder
Depressive states that involve 2 to 4 associated symptoms 
lasting ≥ 2 weeks but ≤ 2 years are sometimes described as 
minor depression, captured in the DSM-5 as “other specified and 
unspecified depressive disorder”. This category may wrongly 
infer low severity and therefore discourage treatment.
Case example
Mrs S, aged 35, presents with depressive symptoms that began 6 
weeks ago. Symptoms include: depressed mood, hopelessness, 
anhedonia, anxiety and insomnia. She denies suicidal ideation. 
She had one previous depressive episode following the birth 
of her second child 2 years prior. The antidepressant sertraline 
(100  mg per day) successfully alleviated her depressive 
symptoms. She has no medical or substance use history of 
note. A mental state examination reveals low mood, tearfulness, 
coherent thought form and no perceptual disturbances. Her 
score on assessment with the Hamilton Depression Rating Scale 
(HAM-D) is 20/30. Physical examination is unremarkable.
Once a diagnosis of MDD is made, Mrs S’ condition can be further 
characterised using specifiers. The first specifier is the severity of 
MDD which needs to be rated as mild, moderate or severe. The 
severity of functional impairment and/or suicidality and/or the 
presence of psychotic symptoms are important indicators of the 
severity of a depressive episode. 
Other specifiers include:
With anxious distress
This specifier refers to prominent anxiety features (feeling 
worried, restless, tense or keyed up; fearful of losing control or 
something terrible happening). Co-occurring anxiety is prevalent 
in patients with MDD, causes impairment and/or distress and 
is associated with the reporting of suicidal thoughts. Anxiety 
symptoms or syndromes occur in at least half of outpatients 
who have MDD and can account for a substantial percentage of 
nonresponse to first-line antidepressant therapy.13
With mixed features
MDD lies on a continuum with bipolar disorder. Patients with 
either diagnosis can manifest some features of the other. For 
example, some patients with MDD may have racing thoughts 
and a reduced need for sleep. At least 3 symptoms of mania 
or hypomania (elevated or expansive mood, heightened self-
esteem or grandiosity, racing thoughts, increased speech or 
pressure of speech, increased energy, excessive involvement in 
behaviour with a potential for negative consequences, and/or 
reduced need for sleep) need to be present. The mixed feature 
specifier can be applied to depressed patients whether or not 
they have ever had a manic or hypomanic episode in the past, 
MDD rather than bipolar disorder remains the overarching 
diagnosis, unless criteria have ever been met for a full mania or 
hypomania in which case the diagnosis of Bipolar Disorder rather 
than MDD needs to be made.
Patients with bipolar depression may be erroneously diagnosed 
initially and treated for Major Depressive Disorder14 and treated 
with antidepressant monotherapy, which is not efficacious as 
stand-alone pharmacotherapy and may be associated with mood 
switching.15 As depression is frequently the presenting mood 
state, screening for previous episodes of hypomania/mania is 
essential. Several additional cues may point to presence of a 
bipolar depression such as early onset, family history of bipolar 
disorder, treatment resistance, number of previous episodes, and 
rapid response to antidepressant therapy.16
With melancholic features
Melancholia involves the cardinal symptoms of anhedonia and 
lack of mood reactivity, alongside features such as distinct quality 
of mood, diurnal variation, excessive guilt, and sever weight loss. 
Melancholic features do not necessarily recur across successive 
episodes of depression. However, melancholic features carry an 
increased risk of psychosis and high-lethality suicidal behaviour.
With atypical features
This comprises a symptom constellation of:
• Reactiveness of mood to environmental stimuli (unlike 
melancholia).
• Heightened interpersonal sensitivity
• Hypersomnia
• Hyperphagia
• Profound fatigue or a sense of physical heaviness
With mood-congruent/ incongruent psychotic features
Psychotic symptoms in MDD are mainly mood-congruent. This 
means that the content of the delusions and hallucinations are 
consistent with the typical themes of depression, such as guilt, 
personal inadequacy, death, disease, and nihilism. Sometimes, 
delusions and hallucinations do not include these depressive 
themes (i.e. are mood-incongruent). The presence of psychosis 
and related components (e.g. mood congruence) is closely 
linked with the severity of depression (high severity) and poorer 
prognosis with implications for treatment.
With Catatonia
The DSM-5 now allows for specification of catatonia in a 
variety of disorders, including depression.8 In previous editions 
catatonia was associated with schizophrenia and listed as a 
subtype. Catatonia refers to psychomotor disturbances. The 
DSM-5 criteria include the presence of three symptoms from 
the following list of twelve: stupor (i.e. no psychomotor 
activity; not actively relating to environment); catalepsy 
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(i.e. passive induction of a posture held against gravity); 
waxy flexibility (i.e. allow positioning by examiner and maintain 
position); mutism; negativism (i.e. opposition or no response to 
instructions or external stimuli); posturing (i.e. spontaneous and 
active maintenance of a posture against gravity); mannerisms (i.e. 
odd, circumstantial caricature of normal actions; stereotypy (i.e. 
repetitive, abnormally frequent, non-goal-directed movements); 
agitation; grimacing; echolalia; and echopraxia. Other common 
symptoms are motor resistance to simple commands, posturing, 
rigidity, automatic obedience, and repetitive movements.
With peripartum onset
The DSM-5 does not recognise postpartum depression as a 
separate diagnosis; rather, a patient must meet the criteria for 
a major depressive episode and the criteria for the peripartum-
onset specifier. The definition is therefore a major depressive 
episode with an onset in pregnancy or within 4 weeks of delivery.
The clinical rationale for including this is to remind clinicians of 
the treatment implications associated with the occurrence of 
MDD in this reproductive period. About half of patients identified 
with postpartum depression will already report an onset of 
symptoms during pregnancy.
With seasonal pattern
DSM-5 identifies “with seasonal pattern” as a specifier for 
recurrent major depression. This is when depressive episodes 
occur in line with seasonal changes.  A winter-type  seasonal 
pattern is most common, especially in higher latitudes, with a 
summer-type seasonal pattern less often diagnosed.
Severity
This provides important details about the presentation and is 
informative for promoting more appropriate treatment. Mild 
major depression can be treated with psychotherapy alone while 
moderate to severe episodes should be treated with medication 
or with a combination of medication and psychotherapy. It is 
important to take patient preference, prior treatment history 
and affordability into account. Moderate-severe and severe 
depression also requires that decisions about treatment setting 
(inpatient or outpatient) and other therapeutic modalities 
be considered (e.g. electroconvulsive therapy which is more 
appropriate than psychotherapy for catatonic depression).
Suicide risk assessment
As part of the clinical evaluation, a comprehensive risk 
assessment needs to be conducted and documented. Evaluate 
the patient for risk and protective factors. Key risk factors include 
previous suicide attempts, a family history of suicide, access to 
lethal means, history of a psychiatric disorder, history of alcohol 
and substance abuse, and severe hopelessness.17
Rating scales and screening tools
There are several brief, useful and easy-to-administer rating-
scales which can be used to guide diagnosis and monitor 
care, and are easily incorporated into clinical practice. This 
information can be used to follow the progression of symptoms 
and effectiveness of treatment. Although rating scales should 
never be used alone to establish a diagnosis or treatment plan, 
they can and should be used to augment information from the 
clinician’s diagnostic assessment and follow-up interviews.
Patient Health Questionnaire (PHQ-9)
The PHQ-9 is a 9-item self-report questionnaire that can assist 
in the detection of depression and supplement a thorough 
psychiatric and mental health status assessment. The PHQ-9 is 
available online at no cost and in several languages and takes 
few minutes to complete.18
Edinburgh Postnatal Depression Scale (EDPS)
This 10-item self-report measure is designed to screen women 
for symptoms of emotional distress during pregnancy and the 
postnatal period.19
Daily Rating of Severity of Problems (DRSPP)
A diagnosis of PMDD requires prospective daily monitoring of 
symptoms for ≥ 2 consecutive months. The widely used DRSPP 
allows clinicians to quantify the severity of physical, emotional, 
and behavioral symptoms, is easy to use in clinical practice, and 
creates a graphic representation of cyclical symptom changes. 
The DRSPP includes all PMDD symptoms and severity ratings 
and is recognised as a valid instrument for diagnosing PMDD.11
Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a 2-page questionnaire that only takes a few 
minutes to administer and can also be completed as a self-
report measure. It can be used to assess severity of and track 
changes over times in suicidal ideation and behaviour. The 
“Lifetime/Recent” version allows clinicians to gather lifetime 
history of suicidality as well as any recent suicidal ideation and/
or behaviour, whereas the “since last visit” version assesses 
suicidality in patients who have completed at least 1 Lifetime/
Recent C-CSSRS assessment.20
Collaborative Assessment and Management of Suicidality 
(CAMS)
The CAMS is a structured, evidence-based method of risk 
assessment and treatment planning. The CAMS provides a 
framework to involve the patient in the assessment of their 
suicidality and to design a suicide-specific treatment plan.21. 
Management
General principles
• Establish a therapeutic alliance; simply seeking psychiatric 
care can bring relief by providing some sense of control over 
distressing symptoms. Validate the patient’s experience, 
normalise their response and instill a sense of hope. Be 
nonjudgmental and empathic as this will help the patient 
accept his/her experiences and emotions. Engage the patient 
as an active participant in their treatment plan.
• Treat comorbid illnesses, being mindful of both disease-
disease, disease-drug and drug-drug interactions. For example, 
depression and cardiovascular disease are often comorbid, 
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and require avoidance of tricyclic antidepressants (TCAs) 
as TCAs may exacerbate cardiac conduction abnormalities. 
Drug-drug interactions are less likely if a medication has a 
wide therapeutic index, is a “weak” inducer or inhibitor of 
metabolism and the patient has normal renal and hepatic 
function.
• Treatment should be guided by subtype as well as severity 
of the depressive disorder (e.g. the management of 
secondary depression involves addressing the underlying 
medical condition and might include use of antidepressant 
medication).
• Pay careful attention to suicidal ideation and suicidality, 
including during antidepressant therapy.
• Coordinate treatment with a psychiatrist and other specialists 
as needed.
Non-pharmacological
• Lifestyle modification
It is important to educate patients about adopting a healthy 
lifestyle; eating wisely, not smoking, sleep hygiene and 
engaging in regular aerobic exercise. Mood episodes have 
been shown to be associated with significant elevations in 
inflammatory cytokines in serum and cerebrospinal fluid (CSF) 
including interleukins, tumor necrosis factor-alpha, interferon 
gamma and C-reactive protein. A sedentary lifestyle increases 
depression risk, whereas regular exercise has been shown to 
down-regulate systemic inflammation. A Mediterranean diet 
which comprises of fruits, vegetables, legumes and food rich in 
omega-3 fatty acids (fish, nuts, leafy green vegetables) has anti-
inflammatory effects.22 Lycopene-containing foods (tomatoes, 
papaya, carrots, watermelon) are rich in antioxidants and thus 
reduce inflammation. Obesity is a pro-inflammatory state, and 
when an obese person loses weight, levels of inflammatory 
markers (interleukin-6, leptin) decrease. Neuroinflammation 
is a well-established underlying mechanism in depression.23 
Encourage the patient to adopt an exercise regimen that is 
appropriate and can be maintained by the patient. 
• Psychotherapy: in addition to developing and sustaining a 
therapeutic alliance, psychotherapy by a trained professional 
can be transformational by helping patients to process 
complex life events and emotions, feel understood, enhance 
self-esteem and overcome psychological barriers to recovery. 
Evidence based psychotherapies (e.g. cognitive behavioural 
therapy (CBT) and interpersonal therapy), as adjuncts to 
pharmacotherapy can further improve outcomes in MDD.24
• Refer patient to local support groups such as the South African 
Depression and Anxiety group (SADAG).
• Phototherapy remains a standard treatment for MDD with 
a seasonal pattern, but lacks demonstrated efficacy in non-
seasonal forms of depression.25
Pharmacological
• Depression is associated with multiple genetic and 
environmental causes, hence it is not surprising that a myriad 
of pharmacological treatments can be used. When deciding 
on the best agent, clinicians should adopt an individualised, 
tiered approach that is guided by, inter alia, symptoms that 
are most prominent, comorbid illness, patient preference, 
medication availability and cost. First-choice agents are 
selective serotonin reuptake inhibitors (SSRIs) and serotonin 
norepinephrine reuptake inhibitors (SNRIs). 
• Renal disease can play a significant role in altering the 
pharmacokinetics of a medication, especially in elimination, 
clearance and plasma protein binding. Dosage adjustment 
and caution are needed when using a psychotropic as 
severity of renal impairment increases. The pharmacokinetics 
of fluoxetine remain unchanged irrespective of the stage of 
renal impairment. Patients in active renal dialysis report good 
tolerability and efficacy.
• Consider ‘symptom targeted, 2 birds with one stone-approach’. 
Consider comorbid disease states that allow for prescribing 
1 medication to treat 2 conditions, thereby reducing pill 
burden (e.g. duloxetine for comorbid depression and diabetic 
neuropathy). In patients who report weight loss and poor 
sleep, a sedating antidepressant such as Mirtazapine may 
be a good option (H1 receptor antagonism dampens satiety 
response, resulting in increased caloric intake).
• For PMDD,antidepressants have been shown to effectively 
ameliorate affective and physical symptoms and improve 
quality of life and psychosocial function in patients with 
PMD.26 However, only antidepressants that affect serotonergic 
– not noradrenergic – transmission are effective in PMDD. 
These include: the tricyclic antidepressant clomipramine, the 
SSRIs citalopram, escitalopram, fluoxetine, paroxetine, and 
sertraline and the serotonin-noradrenergic reuptake inhibitor 
venlafaxine.
• Anxious depression: Serotonergic antidepressants remain the 
mainstay of treatment for depression with anxiety.
• Melancholic depression requires antidepressant treatment or 
ECT rather than psychotherapy. Research indicates that TCS 
might yield better results than SSRIs
• While there are no FDA-approved drugs for treating persistent 
depressive disorder (dysthymia), SSRIs and SNRIs are first-line 
pharmacological agents.
• Avoid polypharmacy, but also do not undertreat. Start with 
1 medication, assess its efficacy, tolerability and safety before 
adding an adjunct. SSRIs and SNRIs are associated with a 
delayed response to treatment (several weeks).
• Regular review is crucial not only for treatment response but 
also for monitoring the emergence of any side-effects. Gradual 
titration can circumvent adverse effects and help establish 
lowest effective dose.
• The continuation period of treatment is dependent on 
whether the depression is a first or recurrent episode. For a first 
episode, a minimum period of 6–9 months of maintenance is 
required. For a recurrent episode, the recommended minimum 
treatment length is 3 years. 
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Conclusion
In summary, depressive disorders are common and associated 
with increased psychosocial morbidity and mortality. Early 
identification and tailored treatment may reduce the impact.
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